This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
The scheme is subject to statutory and regulatory approvals as may be necessary.
Allam was serving recently as the CEO at Public Investment Fund
Global pharmaceutical company having a surgical business concept incepted in Dubai
This digital linking of individual’s health records with ABHA is being carried out extensively across different health facilities of the country
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
The advanced laboratory spread over 2,200 Square feet has multiple laboratory divisions including Hematology, Biochemistry, Clinical pathology, Serology and Microbiology
The newly built centre will work as the state-of-the-art facility for not just ethical animal studies but spans from basic, applied to regulatory animal research.
Her previous role at Novartis, where she was general manager, data & digital, in global drug development, also included accountability for driving the DCT strategy, programs and platforms
Subscribe To Our Newsletter & Stay Updated
